Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Almudena Sánchez Martín, et al.
Journal of Personalized Medicine (2021) Vol. 11, Iss. 4, pp. 293-293
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

Skin Barrier Dysregulation in Psoriasis
Andreas Orsmond, Lara Bereza-Malcolm, Tom Lynch, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 19, pp. 10841-10841
Open Access | Times Cited: 129
New frontiers in personalized medicine in psoriasis
Elisa Camela, Luca Potestio, Gabriella Fabbrocini, et al.
Expert Opinion on Biological Therapy (2022) Vol. 22, Iss. 12, pp. 1431-1433
Closed Access | Times Cited: 55
The impact of gender and sex in psoriasis: What to be aware of when treating women with psoriasis
Carole Guillet, Corsin Seeli, Nina Meienberger, et al.
International Journal of Women’s Dermatology (2022) Vol. 8, Iss. 2, pp. e010-e010
Open Access | Times Cited: 47
Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort
Riccardo Viola, Luca Mastorino, Matteo Megna, et al.
International Journal of Dermatology (2024)
Open Access | Times Cited: 7
Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis
Valerio Caputo, Claudia Strafella, Terenzio Cosio, et al.
Genes (2021) Vol. 12, Iss. 9, pp. 1398-1398
Open Access | Times Cited: 40
Association between HLA DNA Variants and Long-Term Response to Anti-TNF Drugs in a Spanish Pediatric Inflammatory Bowel Disease Cohort
Sara Salvador‐Martín, Paula Zapata-Cobo, Marta Velasco Rodríguez‐Belvís, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 2, pp. 1797-1797
Open Access | Times Cited: 14
Genetic Influence on Treatment Response in Psoriasis: New Insights into Personalized Medicine
Emilio Berna‐Rico, Javier Perez-Bootello, Carlota Abbad‐Jaime de Aragón, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 12, pp. 9850-9850
Open Access | Times Cited: 14
Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review
Ching-Ya Wang, Chuang‐Wei Wang, Chun‐Bing Chen, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 8, pp. 7329-7329
Open Access | Times Cited: 13
Research Trends on TNF-Alpha Polymorphisms and Psoriasis: A Bibliometric Analysis
Yasemin Adalı, Veli Kaan Aydın, Yasemin Şahin, et al.
Acta Medica Nicomedia (2025) Vol. 8, Iss. 1, pp. 23-29
Closed Access
Challenges in Psoriasis Research: A Systematic Review of Preclinical Models
Ana Ubago-Rodríguez, Maria I. Quiñones‐Vico, Manuel Sánchez‐Díaz, et al.
Dermatology (2024) Vol. 240, Iss. 4, pp. 620-652
Closed Access | Times Cited: 4
Bibliometric analysis and description of research trends in the treatment of psoriasis with biologic agents in the past two decades (2004–2023)
Yingdong Wang, Junchen Li, Chenqi Guo, et al.
Journal of Dermatological Treatment (2024) Vol. 35, Iss. 1
Open Access | Times Cited: 3
Psoriasis: An Immunogenetic Perspective
Ayça Kocaağa, Mustafa Kocaağa
Global Medical Genetics (2022) Vol. 09, Iss. 02, pp. 082-089
Open Access | Times Cited: 14
Association between several immune response‐related genes and the effectiveness of biological treatments in patients with moderate‐to‐severe psoriasis
Alba Loras, Marta Gil‐Barrachina, Bárbara Hernando, et al.
Experimental Dermatology (2024) Vol. 33, Iss. 1
Open Access | Times Cited: 2
Dose Adjustment of Biologic Treatments for Moderate-to-Severe Plaque Psoriasis in the Real World: A Systematic Review
Alessio Gambardella, Gaetano Licata, Anne Sohrt
Dermatology and Therapy (2021) Vol. 11, Iss. 4, pp. 1141-1156
Open Access | Times Cited: 17
Neurological Complications of Biological Treatment of Psoriasis
Mateusz Ożóg, Beniamin Oskar Grabarek, Magdalena Wierzbik-Strońska, et al.
Life (2022) Vol. 12, Iss. 1, pp. 118-118
Open Access | Times Cited: 11
TYK2 as a novel therapeutic target in psoriasis
Sarah Elyoussfi, Shraddha S. Rane, Stephen Eyre, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 549-558
Closed Access | Times Cited: 6
Break on through: The role of innate immunity and barrier defence in atopic dermatitis and psoriasis
Heike C. Hawerkamp, Caoimhe Fahy, Padraic G. Fallon, et al.
Skin Health and Disease (2022) Vol. 2, Iss. 2
Open Access | Times Cited: 10
Tailored biological treatment for patients with moderate-to-severe psoriasis
Martina Maurelli, Paolo Gisondi, Giampiero Girolomoni
Expert Review of Clinical Immunology (2022) Vol. 19, Iss. 1, pp. 37-43
Closed Access | Times Cited: 8
Risks of Biologic Therapy and the Importance of Multidisciplinary Approach for an Accurate Management of Patients with Moderate-Severe Psoriasis and Concomitant Diseases
Ana Ion, Alexandra Maria Dorobanțu, Liliana Gabriela Popa, et al.
Biology (2022) Vol. 11, Iss. 6, pp. 808-808
Open Access | Times Cited: 6
Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies
Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Almudena Sánchez Martín, et al.
Pharmaceuticals (2021) Vol. 14, Iss. 9, pp. 905-905
Open Access | Times Cited: 7
Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
Cristina Membrive-Jiménez, Cristina Pérez-Ramírez, Salvador Arias‐Santiago, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 10, pp. 8703-8703
Open Access | Times Cited: 2
FBXL19 promotes malignant behaviours by activating MAPK signalling and negatively correlates with prognosis in hepatocellular carcinoma
Min Xun, Jiming Wang, Qiuli Xie, et al.
Heliyon (2023) Vol. 9, Iss. 11, pp. e21771-e21771
Open Access | Times Cited: 2
Nail Involvement as a Predictor of Differential Treatment Effects of Secukinumab Versus Ustekinumab in Patients with Moderate to Severe Psoriasis
Curdin Conrad, Christine-Elke Ortmann, Marc Vandemeulebroecke, et al.
Dermatology and Therapy (2021) Vol. 12, Iss. 1, pp. 233-241
Open Access | Times Cited: 5
Expression Dynamics Of Cytokine Genes Is Related To The Apremilast Treatment Effectiveness In Patients With Severe Psoriasis
Dmitry A. Verbenko, Arfenya Е. Karamova, Olga G. Artamonova, et al.
Russian Open Medical Journal (2024) Vol. 13, Iss. 1
Open Access
Pharmacogenetics of psoriasis: predictors of the efficacy of anticytokine biological therapy
Е. А. Шатохина, I. G. Egoshina, Anna S. Bridan-Rostovskaya, et al.
Russian Journal of Allergy (2024) Vol. 21, Iss. 1, pp. 167-176
Open Access
Page 1 - Next Page

Scroll to top